Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T18:03:28.400Z.
Calculation as of: 2026-10-06T18:03:28.400Z.
Quote observation: 2026-10-06T18:00:21.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840
PE RATIO
N/A
Market Cap
$982.34M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$973.18M
PE Ratio
70.43
TTM Avg
118.14
3Y Avg
119.36
5Y Avg
99.91
Market Cap
$1.02B
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Latigo Biotherapeutics Inc. (LTGO) | $990.42M | N/A | N/A | N/A | N/A |
| MeiraGTx Holdings plc (MGTX)vs › | $984.44M | 14.97 | 18.35 | 18.35 | 18.35 |
| PROCEPT BioRobotics Corporation (PRCT)vs › | $982.42M | N/A | N/A | N/A | N/A |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $982.34M | N/A | N/A | N/A | N/A |
| Vor Biopharma Inc. (VOR)vs › | $997.50M | N/A | N/A | N/A | N/A |
| Pacira BioSciences, Inc. (PCRX)vs › | $973.18M | 70.43 | 118.14 | 119.36 | 99.91 |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $1.01B | N/A | 5.99 | 5.99 | 5.99 |
| Aktis Oncology, Inc. (AKTS)vs › | $966.09M | N/A | N/A | N/A | N/A |
| Lumexa Imaging Holdings, Inc. Common Stock (LMRI)vs › | $1.02B | N/A | N/A | N/A | N/A |
| Janux Therapeutics, Inc. (JANX)vs › | $1.03B | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
